Guggenheim Capital LLC raised its holdings in Waters Co. (NYSE:WAT) by 39.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 300,143 shares of the medical instruments supplier’s stock after acquiring an additional 84,981 shares during the quarter. Guggenheim Capital LLC owned about 0.38% of Waters worth $57,984,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in WAT. Advisor Partners LLC raised its holdings in shares of Waters by 11.6% during the fourth quarter. Advisor Partners LLC now owns 2,372 shares of the medical instruments supplier’s stock worth $500,000 after acquiring an additional 246 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Waters by 0.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 46,545 shares of the medical instruments supplier’s stock worth $8,992,000 after acquiring an additional 253 shares during the period. LS Investment Advisors LLC raised its holdings in shares of Waters by 7.0% during the fourth quarter. LS Investment Advisors LLC now owns 3,962 shares of the medical instruments supplier’s stock worth $765,000 after acquiring an additional 259 shares during the period. OppenheimerFunds Inc. raised its holdings in shares of Waters by 16.2% during the fourth quarter. OppenheimerFunds Inc. now owns 1,860 shares of the medical instruments supplier’s stock worth $359,000 after acquiring an additional 259 shares during the period. Finally, Chilton Investment Co. LLC raised its holdings in shares of Waters by 6.1% during the fourth quarter. Chilton Investment Co. LLC now owns 4,700 shares of the medical instruments supplier’s stock worth $908,000 after acquiring an additional 269 shares during the period. 94.50% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Mark T. Beaudouin sold 42,143 shares of the company’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $217.21, for a total transaction of $9,153,881.03. Following the completion of the transaction, the senior vice president now directly owns 20,749 shares in the company, valued at approximately $4,506,890.29. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Joann A. Reed sold 1,386 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $194.07, for a total transaction of $268,981.02. The disclosure for this sale can be found here. Insiders sold a total of 75,180 shares of company stock valued at $16,326,519 over the last 90 days. Corporate insiders own 5.07% of the company’s stock.
Shares of Waters stock opened at $211.18 on Thursday. Waters Co. has a 12 month low of $153.04 and a 12 month high of $220.20. The company has a quick ratio of 6.60, a current ratio of 7.04 and a debt-to-equity ratio of 0.85. The firm has a market cap of $16,896.12, a PE ratio of 1,111.53, a price-to-earnings-growth ratio of 2.57 and a beta of 0.91.
Waters (NYSE:WAT) last issued its quarterly earnings data on Tuesday, January 23rd. The medical instruments supplier reported $2.51 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.07. The business had revenue of $687.28 million during the quarter, compared to analysts’ expectations of $671.98 million. Waters had a net margin of 0.88% and a return on equity of 24.70%. The business’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.21 EPS. equities analysts expect that Waters Co. will post 8.16 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on WAT shares. Morgan Stanley upgraded shares of Waters from an “underweight” rating to an “equal weight” rating and set a $192.00 price objective on the stock in a report on Monday, December 4th. Zacks Investment Research raised shares of Waters from a “hold” rating to a “buy” rating and set a $217.00 target price for the company in a research report on Tuesday, December 26th. Evercore ISI started coverage on shares of Waters in a research report on Wednesday, January 3rd. They issued an “in-line” rating and a $198.00 target price for the company. BTIG Research started coverage on shares of Waters in a research report on Friday, January 5th. They issued a “buy” rating and a $230.00 target price for the company. Finally, Barclays reaffirmed a “hold” rating and issued a $202.00 target price on shares of Waters in a research report on Monday, January 8th. Twelve investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $205.13.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/03/22/waters-co-wat-shares-bought-by-guggenheim-capital-llc.html.
Waters Company Profile
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.